Yakult begins Phase 1 multiple myeloma trial with perifosine
03:35 EDT 29 Jun 2012 | Pharmaceutical Business Review
Yakult Honsha, Aeterna Zentaris' Japanese partner, has commenced Phase 1 trial in multiple myeloma with perifosine, an oral Akt/PI3K inhibitor drug.
Original Article: Yakult begins Phase 1 multiple myeloma trial with perifosine
More From BioPortfolio on "Yakult begins Phase 1 multiple myeloma trial with perifosine"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
